Newer long-term treatments for multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 104, Issue 3, 2002, Pages 265-271

  Pryse Phillips, William ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cost; Glatiramer acetate; Interferon; Quality of life; Treatment

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; COST; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HUMAN; LONG TERM CARE; MEDICAL ETHICS; MULTIPLE SCLEROSIS; PLASMAPHERESIS; QUALITY OF LIFE; RELAPSE; REMISSION;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANTIBODY FORMATION; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; ETHICS, MEDICAL; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; PLASMAPHERESIS; PROGNOSIS; QUALITY OF LIFE; RECURRENCE;

EID: 0036074622     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-8467(02)00050-1     Document Type: Conference Paper

References (51)

1. Interferon β-1b is effective in the treatment of multiple sclerosis
2. Interferon 1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicentre randomized, double-blind placebo-controlled trial
3. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial
4. New treatments for multiple sclerosist a clinical perspective
5. Interferon 1b in secondary progressive MS, clinical and MRI results of a 3 year randomized controlled trial
6. Results of the 3 year, double-blind placebo-controlled study of interferon β-1a (Rebif) in secondary progressive multiple sclerosis
7. Relapsing versus nonrelapsing MS: different prognosis and response to interferon therapy in the SPECTRIMS study
8. Multiple sclerosis
9. Disease modifying drugs for multiple sclerosis: a rapid and systematic review
10. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
11. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis
12. Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis
13. Randomised, double blind, controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analyzed by area under disability/time curves
14. Evidence of interferon β-1a dose response in relapsing-remitting MS: the OWIMS study
15. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis
16. Low dose oral methotrexate in chronic progressive multiple sclerosis
17. Intramuscular interferon β-1a initiated during a first demyelinating event in multiple sclerosis
18. Extended observations on MS patients treated with IM interferon-β-1a (Avonex): implications for modern MS trials and therapeutics
19. Extended observations on MS patients treated with IM interferon-β-1a (Avonex): implications for modern MS trials and therapeutics
20. Recombinant interferonβ-1a
21. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis
22. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis
23. The effects of glatiramer acetate (Copaxone) in disease activity as measured by MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multicenter, randomized, double-blind, placebo-controlled study extended by open-label treatment
24. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
25. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis
26. Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis
27. Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course
28. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progresive multiple sclerosis
29. Assessment of plasmapheresis
30. Intravenous immunoglobulin treatment in multiple sclerosis
31. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
32. Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity
33. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
34. Overview of azathioprine treatment in multiple sclerosis
35. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
36. Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
37. Therapeutic effect of mitoxantrone combined with methylprednisoloone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria
38. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis, 24 month clinical and MRI outcome
39. Cladribine in treatment of chronic progressive multiple sclerosis
40. Treatment of multiple sclerosis and other diseases with cladribine
41. Why treat early multiple sclerosis patients
42. Multiple sclerosis-from probable to definite diagnosis
43. To treat or not to treat
44. Drug treatment of multiple sclerosis
45. Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b
46. Guidelines for physicians with patients on IFNβ-1b
47. Population based cost utility study of interferon β-1b in secondary progressive multiple sclerosis
48. Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life
49. A cost-utility analysis of interferon beta for multiple sclerosis
50. The quality of life effects of interferon-β 1b in multiple sclerosis, an extended Q-twist analysis